Literature DB >> 24047072

Acquired resistance to crizotinib from a mutation in CD74-ROS1.

Mark M Awad, Jeffrey A Engelman, Alice T Shaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24047072     DOI： 10.1056/NEJMc1309091

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Reading between the lines; understanding drug response in the post genomic era.

Authors:  Constantine C Alifrangis; Ultan McDermott
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

Review 2.  Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

Authors:  Mukesh Kumar; Vinicius Ernani; Taofeek K Owonikoko
Journal:  Mol Aspects Med       Date:  2015-07-14

3.  A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.

Authors:  Motonobu Saito; Kouya Shiraishi; Kenji Matsumoto; Aaron J Schetter; Hiroko Ogata-Kawata; Naoto Tsuchiya; Hideo Kunitoh; Hiroshi Nokihara; Shun-Ichi Watanabe; Koji Tsuta; Kensuke Kumamoto; Seiichi Takenoshita; Jun Yokota; Curtis C Harris; Takashi Kohno
Journal:  Clin Cancer Res       Date:  2014-08-20       Impact factor: 12.531

Review 4.  Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.

Authors:  Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2014-05-01       Impact factor: 12.531

5.  Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Authors:  Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Ali Amin-Mansour; Amaro Taylor-Weiner; Mara Rosenberg; Nathanael Gray; Justine A Barletta; Yanan Guo; Scott J Swanson; Daniel T Ruan; Glenn J Hanna; Robert I Haddad; Gad Getz; David J Kwiatkowski; Scott L Carter; David M Sabatini; Pasi A Jänne; Levi A Garraway; Jochen H Lorch
Journal:  N Engl J Med       Date:  2014-10-09       Impact factor: 91.245

Review 6.  The impact of fusion genes on cancer stem cells and drug resistance.

Authors:  Saurav Panicker; Sivaramakrishnan Venkatabalasubramanian; Surajit Pathak; Satish Ramalingam
Journal:  Mol Cell Biochem       Date:  2021-06-07       Impact factor: 3.396

Review 7.  NTRK fusion-positive cancers and TRK inhibitor therapy.

Authors:  Emiliano Cocco; Maurizio Scaltriti; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2018-12       Impact factor: 66.675

8.  Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.

Authors:  Kristina B Emdal; Antje Dittmann; Raven J Reddy; Rebecca S Lescarbeau; Sheri L Moores; Sylvie Laquerre; Forest M White
Journal:  Mol Cancer Ther       Date:  2017-08-22       Impact factor: 6.261

9.  The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.

Authors:  Zhaoting Meng; Ting Li; Pei Wang; Analyn Lizaso; Dingzhi Huang
Journal:  Cancer Biol Ther       Date:  2020-12-30       Impact factor: 4.742

10.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.